Primary CD8+ Cytotoxic T Cells from ATCC

Product Specs
ItemPrimary CD8+ Cytotoxic T Cells
CompanyATCC
Price $1,842.00Supplier Page View Company Product Page
Catalog NumberPCS-800-017
Quantity>= 2.5 x 10^6
ApplicationsResearch purposes, compound screening, immune function assays
TypeCell Biology
SpeciesHomo sapiens
Volume1.0 mL
Research Area3D cell culture, Immunology, Toxicology, Immuno-oncology, Cell and gene therapy (CGT) development
GenderLot specific
Agelot-specific
Diseasenormal
TissueBlood

Add to Compare List

ATCC

10801 University Boulevard

Manassas, Virginia 20110-2209

United States

Phone: (703) 365-2700
Fax: (703) 365-2701

Company Profile

Website: http://www.atcc.org

(1) Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept studyNature CommunicationsMarch 16, 2026Junya Tabata, Tzu-Ting Huang, Elena Giudice, Kristen R. Ibanez, Jayakumar R. Nair, Aanika Balaji Warner, Britanny B. Solarz, Valentina Bolanos, Bernadette Redd, Nahoko Sato, et al.activation for in vitro T-cell co-culture experiments Primary human CD8⁺ T cells were purchased from ATCC (#PCS-800-017, Manassas, VA, USA), and cultured in RPMI-1640 supplemented with 10% FBS and recombinant human IL-2

(2) The mechanism by which KAT2A increases the stability of CDC25A through acetylation to regulate glycolysis and mediate lung adenocarcinoma immune escapeRespiratory ResearchFebruary 5, 2026Wenyu Chen, Xiaoli Tan, Qi Yang, Chunsheng Bai, Yufen Xucell lines, including A549 (BNCC337696), H1299 (BNCC100268), and Calu-3 (BNCC359757). CD8+T cells (PCS-800-017™) were from ATCC (USA), and mouse LUAD cells LLC (SNL-119) from SUNNCELL (China). All cell lines were

(3) Novel Disulfiram-Loaded Metal–Organic Nanoparticles Inhibit Tumor Growth and Induce Immunogenic Cell Death of Triple-Negative Breast Cancer CellsPharmaceuticsNovember 9, 2025Chung-Hui Huang, Xuejia Kang, Lang Zhou, Junwei Wang, Shuai Wu, Peizhen Sun, Qi Wang, Adam B. Keeton, Pengyu Chen, Gary A. Piazzamammary carcinoma cell line (ATCC), U937-DC-SIGN (CRL-2539, ATCC), primary CD8+ cytotoxic T cells (PCS-800-017™, ATCC), THP-1 Dual™ NF-κB/IRF reporter cells (CRL-3253™, ATCC), and DC2.4 mouse dendritic cell line

(4) MiR-518c-5p/miR-4524a-3p can mediate immune escape and chemotherapy resistance in triple-negative breast cancer and predict its outcomeHereditasOctober 21, 2025Yuan Sun, Liang An, Linna Kong, Xiaoyan Liu, Huihui Zhang, Jiaqi Liu, Pengfei Qianfrom ATCC (CRL-10317) and cultured in DMEM medium with 10% FBS. CD8⁺ T cells were obtained from ATCC (PCS-800-017). The overexpression of MHCI (oeMHCI), empty vector plasmids and lentivirus-mediated knockdown (shMHCI)

(5) Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancerResearch SquareOctober 5, 2025Jung-Min Lee, Junya Tabata, Tzu-Ting Huang, Elena Giudice, Kristen Ibanez, Jayakumar Nair, Aanika Warner, Britanny Solarz, Valentina Bolanos, Bernadette Redd, et al.(#LT-07-318, Lonza, Portsmouth, NH, USA). CD8+ T Cell isolation and activation Primary human CD8+ T cells (#PCS-800-017, ATCC, Manassas, VA, USA) were thawed and cultured in RPMI-1640 supplemented with 10% FBS and recombinant

(6) Sennoside A Modulates the Ferroptosis and Immune Evasion of Oral Squamous Cell Carcinoma Cells Through Inhibiting the NF-κB PathwayIntegrative Cancer TherapiesSeptember 17, 2025Jiaying Huo, Jianhua Qi, Qixuan Rento cultivate human CD8+ T cells from the American Type Culture Collection (ATCC, Manassas, VA, Cat# PCS-800-017) at 37°C with 5% CO2. Cell Counting Kit-8 (CCK-8) Assays HOK cells with a density of 1 × 105 cells/well

(7) Therapeutic Efficacy of CD34-Derived Allogeneic Dendritic Cells Engineered to Express CD93, CD40L, and CXCL13 in Humanized Mouse Models of Pancreatic CancerVaccinesJuly 12, 2025Huerta-Yepez S, Gonzalez JD, Sheik N, Beraki S, Kathirvel E, Rodriguez-Frandsen A, Chen PC, Sargsyan T, Mahammad S, Dybul MR, et al.fetal bovine serum (FBS) to a final concentration of 10%. Human PBMCs (ATCC [PCS-800-011]), T cells (ATCC [PCS-800-016, PCS-800-017]), SNU 423 cells (ATCC [CRL-5971]) and other immune cells were cultured as per the manufacturer’s recommendations

(8) Thrombospondin-1 induces CD8+ T cell exhaustion and immune suppression within the tumor microenvironment of ovarian cancerJ Ovarian ResMay 10, 2025Haiyan Liang, Suwei Zhang5% CO2. The human monocyte macrophage cell line THP-1 (#TIB-202, ATCC) and CD8+ cytotoxic T cells (#PCS-800-017) were cultured in RPMI-1640 medium supplemented with 10% FBS and 1% P/S. To investigate the role of

(9) Shape‐Versatile Fixed Cellular Materials for Multiple Target ImmunomodulationAdvanced MaterialsJuly 1, 2024Ana Rita Sousa, Ana F. Cunha, Ana Santos‐Coquillat, Beatriz Hernaez Estrada, Kara L. Spiller, Marta Barão, Artur Filipe Rodrigues, Susana Simões, Andreia Vilaça, Lino Ferreira, et al.primary human CD4+ T cells, and CD8+ T cells were purchased from ATCC (cat.: TIB-202, PCS-800-016, and PCS-800-017, respectively). THP1-Lucia NF-κB reporter cells were acquired from InvivoGen. All cells were cultured

(10) CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancerJournal of experimental & clinical cancer research : CRApril 16, 2024Zhao Y, Yu Y, Li X, Guo A.Cell culture Human TNBC cells MDA-MB-231 (HTB-26) and MDA-MB-468 (HTB-132) and CD8+ cytotoxic T cells (PCS-800–017) were procured from ATCC (Manassas, VA, USA). Another TNBC cell line, MDA-MB-453 (BNCC340797), was acquired

(11) RNF182 induces p65 ubiquitination to affect PDL1 transcription and suppress immune evasion in lung adenocarcinomaImmunity, inflammation and diseaseMay 1, 2023Zeng X, Tang X, Chen X, Wen H.(LDH) kit (C0016; Beyotime). LUAD cells were used as target cells, while the CD8+ cytotoxic T cells (PCS‐800‐017; ATCC) were used as the effector cells. In short, 4 × 105 LUAD cells and 6 × 105 T cells were seeded

(12) SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assemblyThe Journal of experimental medicineFebruary 6, 2023Onnis A, Andreano E, Cassioli C, Finetti F, Della Bella C, Staufer O, Pantano E, Abbiento V, Marotta G, D'Elios MM, et al.

(13) Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian CancerMolecular Cancer TherapeuticsNovember 1, 2020Mark Seungwook Kim, Shaolin Ma, Anca Chelariu-Raicu, Carola Leuschner, Hector W. Alila, Sanghoon Lee, Robert L. Coleman, Anil K. Soodovarian cancer (SKOV3ip1) and murine immortalized fibroblast (NIH-3T3) and human CD8+ cytotoxic T cells (ATCC® PCS-800–017™) were obtained from the American Type Culture Collection. Unless indicated otherwise, all in vitro

(14) Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancerMol Cancer TherSeptember 17, 2020Mark Seungwook Kim, Shaolin Ma, Anca Chelariu-Raicu, Carola Leuschner, Hector W. Alila, Sanghoon Lee, Robert L. Coleman, Anil K. Soodovarian cancer (SKOV3ip1) and murine immortalized fibroblast (NIH-3T3) and human CD8+ cytotoxic T cells (ATCC® PCS-800–017™) were obtained from the American Type Culture Collection. Unless indicated otherwise, all in vitro

(15) Tadpole serum activity (Rana catesbeian a) in caspase-3 as a marker of the role of apoptosis and total cytotoxic T lymphocytes in albino rats' epithelial cells induced by neoplasiaVeterinary WorldJanuary 10, 2019M. T. E. Purnama, I. H. Rahmaningtyas, A. R. Pratama, Z. Prastika, A. M. Kartikasari, N. P. D. Cahyocaspase-3 anti-rat (PE Active Caspase-3 Apoptosis Kit BD Pharmingen™ with CAS number 550914) and CTL (ATCC® PCS800-017™) for 1 h in 27°C. The dilution was given 10 µl for caspase-3 and 0.1 ml for CTL test. Caspase-3 was

(16) Identification of lineage-specifying cytokines that signal all CD8⁺-cytotoxic-lineage-fate 'decisions' in the thymusNature immunologyNovember 1, 2017Etzensperger R, Kadakia T, Tai X, Alag A, Guinter TI, Egawa T, Erman B, Singer A.

(17) Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancerJournal for immunotherapy of cancerJanuary 1, 2017Fortis SP, Sofopoulos M, Sotiriadou NN, Haritos C, Vaxevanis CK, Anastasopoulou EA, Janssen N, Arnogiannaki N, Ardavanis A, Pawelec G, et al.

Be the First to Write a Review!